KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Accumulated Expenses (2016 - 2026)

Abbott Laboratories' Accumulated Expenses history spans 18 years, with the latest figure at $1.2 billion for Q1 2026.

  • On a quarterly basis, Accumulated Expenses rose 3.86% to $1.2 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.2 billion, a 3.86% increase, with the full-year FY2025 number at $1.7 billion, up 2.59% from a year prior.
  • Accumulated Expenses hit $1.2 billion in Q1 2026 for Abbott Laboratories, down from $1.7 billion in the prior quarter.
  • Over the last five years, Accumulated Expenses for ABT hit a ceiling of $1.7 billion in Q4 2025 and a floor of $1.1 billion in Q1 2024.
  • Historically, Accumulated Expenses has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2022.
  • Biggest five-year swings in Accumulated Expenses: fell 4.27% in 2023 and later rose 11.59% in 2025.
  • Tracing ABT's Accumulated Expenses over 5 years: stood at $1.6 billion in 2022, then rose by 2.63% to $1.6 billion in 2023, then rose by 6.51% to $1.7 billion in 2024, then rose by 2.59% to $1.7 billion in 2025, then crashed by 30.54% to $1.2 billion in 2026.
  • Business Quant data shows Accumulated Expenses for ABT at $1.2 billion in Q1 2026, $1.7 billion in Q4 2025, and $1.7 billion in Q3 2025.